Solid Tumor Oncology Education Foundation Sponsors Free Local Seminars

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

SECAUCUS, NJ--To accommodate community-based physicians who may not be able to attend national professional meetings, the newly formed not-for-profit Solid Tumor Oncology Education Foundation, Inc. will sponsor a series of free local seminars and audioconferences, led by a faculty of expert physicians.

SECAUCUS, NJ--To accommodate community-based physicians who maynot be able to attend national professional meetings, the newlyformed not-for-profit Solid Tumor Oncology Education Foundation,Inc. will sponsor a series of free local seminars and audioconferences,led by a faculty of expert physicians.

The programs will focus on breast, colorectal, gastrointestinal,genitourinary, gynecologic, pancreatic, and lung cancers, andinclude such subjects as adjuvant and palliative therapy, currentand new protocol regimens, screening and diagnosis, and quality-of-lifeissues.

Beginning this month, the Foundation will offer a series of presentationsconducted at local, state, and regional oncology meetings by leadingoncolo-gists, as well as telephone audioconfer-ences, allowinghealth-care professionals to participate from their home or office.

The chairman of the Foundation is Paul A. Bunn, Jr., MD, Universityof Colorado Cancer Center. Board members are Laurence H. Baker,DO, University of Michigan Comprehensive Cancer Center; GabrielN. Hortobágyi, MD, University of Texas M.D. Anderson CancerCenter; John S. Macdonald, MD, Temple University Cancer Center;Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, and ElizabethJ. Shpall, MD, University of Colorado Health Sciences Center.

The formation of the Foundation was made possible by an unrestrictededucational grant from Lilly Oncology. Oncolo-gists can get moreinformation by calling 1-800-223-8978.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content